Bris­tol My­er­s' can­cer drug Aug­ty­ro wins new ac­cel­er­at­ed ap­proval in sol­id tu­mors

Bris­tol My­ers Squibb’s 2022 buy­out of Turn­ing Point Ther­a­peu­tics for $4.1 bil­lion con­tin­ues to score wins at the FDA.

On Thurs­day,

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.